WO2018202870A1 - Peptides for treatment of diabetes - Google Patents

Peptides for treatment of diabetes Download PDF

Info

Publication number
WO2018202870A1
WO2018202870A1 PCT/EP2018/061547 EP2018061547W WO2018202870A1 WO 2018202870 A1 WO2018202870 A1 WO 2018202870A1 EP 2018061547 W EP2018061547 W EP 2018061547W WO 2018202870 A1 WO2018202870 A1 WO 2018202870A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
peptide
agent
amino acid
agent according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2018/061547
Other languages
English (en)
French (fr)
Inventor
Jan Alenfall
Pontus DUNÉR
Anna HULTGÅRDH NILSSON
Björn Walse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Follicum AB
Original Assignee
Follicum AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201880026723.5A priority Critical patent/CN110545834B/zh
Priority to SG11201908513R priority patent/SG11201908513RA/en
Priority to AU2018262805A priority patent/AU2018262805B2/en
Priority to BR112019021886-6A priority patent/BR112019021886A2/pt
Priority to JP2019555219A priority patent/JP2020518556A/ja
Priority to PL18721806T priority patent/PL3618845T3/pl
Priority to IL270199A priority patent/IL270199B2/en
Priority to ES18721806T priority patent/ES2857749T3/es
Priority to DK18721806.0T priority patent/DK3618845T3/da
Priority to EP18721806.0A priority patent/EP3618845B1/en
Priority to EA201992562A priority patent/EA201992562A1/ru
Application filed by Follicum AB filed Critical Follicum AB
Priority to KR1020197027946A priority patent/KR102700014B1/ko
Priority to MX2019013096A priority patent/MX2019013096A/es
Priority to CA3061935A priority patent/CA3061935A1/en
Publication of WO2018202870A1 publication Critical patent/WO2018202870A1/en
Priority to ZA2019/05891A priority patent/ZA201905891B/en
Priority to US16/666,960 priority patent/US10815283B2/en
Anticipated expiration legal-status Critical
Priority to US17/022,526 priority patent/US20210009648A1/en
Priority to JP2023051477A priority patent/JP2023082076A/ja
Priority to JP2025037548A priority patent/JP2025090703A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • C12N9/1088—Glutathione transferase (2.5.1.18)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01018—Glutathione transferase (2.5.1.18)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Definitions

  • the present disclosure relates to peptides useful for treatment of diabetes and associated disorders.
  • the peptide hormone insulin which is produced by ⁇ -cells in the islets of Langerhans in the pancreas, is released in response to increasing blood glucose levels.
  • glucose is removed from the blood by insulin dependent stimulation of glucose transporters located in the cell membranes of the target tissue, e.g. adipose tissue, skeletal muscle and liver.
  • Insulin exerts its biological effects by binding to and activating the membrane-bound insulin receptor (IR), thereby initiating a cascade of intracellular signalling events, which regulate multiple biological processes such as glucose and lipid metabolism.
  • IR membrane-bound insulin receptor
  • GLP-1 glucagon-like peptide-1
  • GLP-1 is a metabolic hormone that stimulates insulin secretion. Besides increasing insulin secretion from the pancreas in a glucose-dependent manner, GLP-1 is known to increase insulin-sensitivity in both a- and ⁇ -cells; to increase ⁇ -cell mass and insulin expression, post-translational modification, and secretion; and to decrease glucagon secretion from the pancreas.
  • Other medications used complementary to insulin treatment for the purpose of lowering plasma glucose levels include DPP-IV inhibitors, Metformin, SGLT-2 inhibitors and sulfonylurea.
  • the present inventors have found peptides which stimulate ⁇ — cell proliferation, have the ability to rescue ⁇ — cell from apoptosis induced by glucotoxic conditions, and stimulate insulin secretion from rat INS-1 ⁇ — cells as well as isolated mouse pancreatic islets. Furthermore, the present inventors found that in a glucose tolerance test, the peptides lowered plasma glucose levels in vivo and delayed onset of diabetes disease in BB lyp/lyp rats, a model for type 1 diabetes. Hence, the peptides of the present disclosure are suitable for use in the treatment of endocrine, nutritional and metabolic diseases and disorders.
  • the present disclosure relates to an agent comprising or consisting of: a) a peptide or peptide analog, wherein the peptide or peptide analog comprises an amino acid sequence of the general formula:
  • X 2 is C, P or G
  • X 5 is E or G
  • X 6 is C, D or I
  • X 7 is D, I, S or G
  • X 8 is S, D or G
  • the peptide comprises no more than 85 amino acid residues.
  • biologically active fragment and/or variant thereof wherein said biologically active fragment and/or variant is selected from the group consisting of CLAEIDSC (SEQ ID NO: 142), CFKPLAEIDSIECSYGIK (SEQ ID NO: 143), KPLAEGDIELSYGIK (SEQ ID NO: 147), KPLAEIELSYGIK (SEQ ID NO: 148), KCLAEIDSCELSYGIK (SEQ ID NO: 155), and CFKPLAEIDSIEC (SEQ ID NO: 156);
  • CLAEIDSC SEQ ID NO: 142
  • CFKPLAEIDSIECSYGIK SEQ ID NO: 143
  • KPLAEGDIELSYGIK SEQ ID NO: 147
  • KPLAEIELSYGIK SEQ ID NO: 148
  • KCLAEIDSCELSYGIK SEQ ID NO: 155
  • CFKPLAEIDSIEC SEQ ID NO: 156
  • the present disclosure relates to an agent comprising:
  • VDTYDGGISVVYGLR (SEQ ID NO: 138), and VDTYDGDGSVVYGLR (SEQ ID NO: 139).
  • VDVPEGDISLAYGLR (SEQ ID NO: 157), LDGLVRAYDNISPVG (SEQ ID NO: 158), GDPNGDISVVYGLR (SEQ ID NO: 159), VDVPNGDISLAYRLR (SEQ ID NO: 160) VDVPEGDISLAYRLR (SEQ ID NO: 161 ), V(beta- D)TYDG D I S VVYG LR (SEQ ID NO:167), VDTY(beta- D)G D IS VVYG LR (SEQ ID NO: 168), VDTYDG(beta- D)ISVVYGLR (SEQ ID NO:169); a polynucleotide encoding upon expression, the peptide of a);
  • a cell comprising the polynucleotide of b), or the vector of c).
  • the present disclosure relates to a composition comprising the agent described herein above.
  • the present disclosure relates to an agent or a composition comprising said agent, for use as a medicament.
  • the present disclosure relates to an agent comprising:
  • X 2 is C, P or G;
  • X 5 is E or G;
  • X 6 is C, D or I
  • X 7 is D, I, S or G
  • X 8 is S, D or G
  • the peptide comprises no more than 25 amino acid residues
  • a peptide wherein the peptide comprises an amino acid sequence of the general formula: VDZ 3 Z 4 Z 5 GZ 7 Z 8 SZ 1 oZ 11 YGLR (SEQ ID NO: 68) wherein:
  • Z 3 is T or V
  • Z 4 is Y or P
  • Z 5 is D or N
  • Z 7 is D or G
  • Z 8 is I or G
  • a peptide wherein the peptide comprises or consists of an amino acid sequence selected from the group consisting of KCLAECDSIELSYGIK
  • endocrine disease for use in the treatment of an endocrine disease, a nutritional disease and/or a metabolic disease in a mammal.
  • the present disclosure concerns a method for treating an endocrine disease a nutritional disease and/or a metabolic disease, the method comprising administering a therapeutically effective amount of an agent described herein, to an individual in need thereof.
  • the present disclosure concerns the use of an agent as described herein for the manufacture of a medicament for the treatment of an endocrine disease a nutritional disease and/or a metabolic disease.
  • the present disclosure concerns a method for delaying onset of diabetes, the method comprising administering a therapeutically effective amount of an agent described herein, to an individual in need thereof.
  • the present disclosure concerns a method for decreasing blood glucose levels, the method comprising administering a therapeutically effective amount of an agent described herein, to an individual in need thereof.
  • the present disclosure concerns a method, e.g. an in vitro method, for improving beta cell morphology, the method comprising administering a therapeutically effective amount of an agent described herein, to an individual in need thereof.
  • the present disclosure concerns a method for improving beta cell viability, the method comprising administering a therapeutically effective amount of an agent described herein, to an individual in need thereof.
  • the present disclosure concerns the use of agent described herein for the preparation of a diagnostic composition for the diagnosis of a disease, disorder or damage of the pancreas in an individual.
  • INS-1 cells incubated during 48h in 20 mM glucose displayed more apoptotic cells (Annexin V positive) compared to cells incubated at 5 mM glucose.
  • Addition of FOL- 005 to cells incubated with 20 mM glucose reduced the level of apoptotic cells compared to 20 mM glucose alone (Fig. 2A).
  • Apoptosis measured by caspase-3 activity was increased in INS-1 cells at 20 mM compared to 5 mM glucose.
  • Addition of FOL-005 diminished the rate of glucotoxicity-induced caspse-3 activity (Fig. 2B).
  • Mean ⁇ SD are presented for 4-8 different observations in each group.
  • FOL-005 stimulated ⁇ -cell and islet insulin secretion. Insulin release from INS-1 cells was increased after FOL-005 (6 ⁇ ) stimulation in-non glucose containing media compared to non-stimulated control (ctrl) and to a scrambled control peptide (FOL-015) (Fig. 3A). FOL-005 stimulated insulin release from INS-1 at both low (5 mM) and high (20 mM) glucose (Fig. 3B). Isolated mouse pancreatic islets stimulated with FOL-005 (6 ⁇ ) or GLP-1 (100 nM) secreted more insulin compared to unstimulated control islets (Fig. 3C). Mean ⁇ SD are presented for 5-6 different observations in each group. Figure 4. Insulin secretion was increased from islets and ⁇ -cells following FOL-014 stimulation
  • FOL-014 stimulated insulin secretion from ⁇ -cells and pancreatic islets.
  • INS-1 cells stimulated with FOL-014 (6 ⁇ ) secreted more insulin compared to unstimulated control cells (Fig. 4A).
  • Isolated mouse pancreatic islets stimulated with FOL-014 (6 ⁇ ) secreted more insulin compared to control islets (Fig. 4B).
  • Mean ⁇ SD are presented for 5-6 different observations in each group.
  • FIG. 5 The effect of FOL-014 on insulin secretion was dose dependent. Stimulation of INS-1 cells by increasing doses of FOL-014 resulted in a significant increase in insulin secretion for all concentrations tested. The insulin secretion increased in a linear fashion in the presence of FOL-014 ranging from 0.6 nM to 60 nM. Higher
  • FOL-014 induced insulin secretion was comparable to the effect of 100 nM GLP-1 . Bars represent mean values and standard error of the mean (SEM). Figure 6. The effect on insulin secretion of FOL-014 was glucose concentration dependent. The insulin secretion from untreated or FOL-014 exposed INS-1 cells was measured in the presence of increasing glucose concentrations. At glucose levels 5.5 mM or higher, the insulin secretion was significantly higher in the FOL-014 treated cells, as compared to untreated control cells. Bars represent mean values and standard error of the mean (SEM).
  • FIG. 7 FOL-005 and FOL-014 dosed together with native GLP- 1 elicited an additive effect on insulin secretion.
  • the insulin release from INS-1 cells was measured following combination treatment of GLP-1 together with FOL-005 and FOL-014 (all three peptides in a concentration of 100 nM), respectively and compared with the effect of each peptide alone.
  • the combination of GLP-1 and FOL-014 significantly increased the insulin secretion as compared with each peptide alone.
  • An increase was also observed for the combination of FOL-005 and GLP-1 . Bars represent mean values and standard error of the mean (SEM).
  • FIG. 8 FOL-014 affected insulin and glucagon secretion in pancreatic islets. Two different concentrations of FOL-014 were tested and compared with the effect of 100 nM GLP-1 on isolated mouse islets in low (2.8 mM) (A, C) and high (16.7mM) (B, D) concentrations of glucose. In the low glucose samples, the presence of FOL-014 did not increase insulin secretion, but reduced glucagon secretion as compared with control and GLP-1 . In the high glucose samples, 600 nM FOL-014 and GLP-1 , but not 6 ⁇ FOL-014, significantly increased insulin secretion (B), and GLP-1 as well as both concentrations of FOL-014 efficiently reduced glucagon secretion (D). Bars represent mean values and standard error of the mean (SEM).
  • FIG. 9 FOL-014 lowered plasma glucose levels in vivo following a glucose injection.
  • IPGTT intraperitoneal glucose tolerance test
  • the dotted line corresponds to mean non-fasting glucose levels.
  • Data represents mean values and standard error of the mean (SEM). Statistical analysis was performed using student's t-test.
  • BB lyp/lyp rats treated with FOL-014 showed a significant delay in the onset of diabetes defined as plasma glucose ⁇ 1 1 .1 mmol/l.
  • Age of onset of diabetes for each rat was depicted in (A) with a significant difference between untreated and treated groups.
  • the percentage of animals developing type 1 diabetes each day was depicted in (B) with a significant difference between groups.
  • Error bars in (A) represent standard error of the mean (SEM).
  • Figure 11 The effect on insulin secretion of peptide analogues derived from FOL-005 or FOL-014. Novel peptide analogues were tested in two separate INS-1 cell lines (A and B) for their ability to induce insulin secretion under high glucose (16.7 mM) conditions.
  • the present disclosure concerns a peptide or a peptide analog comprising an amino acid sequence of the general formula:
  • X 2 is C, P or G
  • Xs is E or G
  • X 6 is C, D or I
  • X 7 is D, I, S or G
  • X 8 is S, D or G
  • X 12 is S or T
  • the peptide comprises no more than 25 amino acids
  • the present disclosure concerns a peptide or a peptide analog comprising an amino acid sequence of the general formula:
  • X 2 is C, P or G
  • Xs is E or G
  • X 6 is C, I or absent
  • X 7 is D, G or absent
  • X 8 is S, G or absent
  • the present disclosure concerns a peptide comprising an amino acid sequence of the general formula:
  • X 2 is C, P or G
  • X 5 is E or G
  • the present disclosure concerns an agent comprising:
  • a peptide comprising or consisting of the amino acid sequence of SEQ ID NO: 136, 141 , 142, 143, 144, 145, 146, 147, 148, 149, 150, 151 , 152, 153, 154, 155, and 156; a biologically active sequence variant of any one of the peptides of i), wherein any one amino acid has been altered for another proteinogenic or non-proteinogenic amino acid, with the proviso that no more than five amino acids are so altered; a biologically active fragment of the peptide of any one of i) or ii), wherein the fragment comprises at least 10 consecutive amino acids of any one of i) or ii); b) a polynucleotide encoding upon expression, the peptide of a);
  • the present disclosure concerns an agent comprising:
  • VDVPEGDISLAYGLR (SEQ ID NO: 157), LDGLVRAYDNISPVG (SEQ ID NO: 158), GDPNGDISVVYGLR (SEQ ID NO: 159), VDVPNGDISLAYRLR (SEQ ID NO: 160) VDVPEGDISLAYRLR (SEQ ID NO: 161 ); b) a polynucleotide encoding upon expression, the peptide of a);
  • the present disclosure concerns a peptide comprising an amino acid sequence of the general formula:
  • VDVPZ 5 GDISLAYZ 13 LR (SEQ ID NO: 164)
  • Z 5 is E or N
  • Z 13 is R or G.
  • the present disclosure concerns a peptide comprising an amino acid sequence of the general formula:
  • VDTYDGZ 7 Z 8 S VVYG LR (SEQ I D NO : 165)
  • Z 7 is D or G
  • Z 8 is I or G.
  • the present disclosure concerns a peptide comprising an amino acid sequence of the general formula:
  • Z 5 is D or G
  • Z 6 is D or G
  • Z 7 is I or R
  • Z 8 is G or absent
  • Z 9 is D or absent.
  • X 6 is C, I or absent
  • peptide analog refers to a peptide comprising or consisting of a non-naturally occurring peptide.
  • 'amino acid' as used herein includes the standard twenty genetically-encoded amino acids and their corresponding stereoisomers in the 'D' form (as compared to the natural V form), omega-amino acids and other naturally-occurring amino acids, unconventional amino acids (e.g., ⁇ , ⁇ -disubstituted amino acids, N-alkyl amino acids, etc.) and chemically derivatized amino acids (see below).
  • unconventional amino acids e.g., ⁇ , ⁇ -disubstituted amino acids, N-alkyl amino acids, etc.
  • chemically derivatized amino acids see below.
  • an amino acid is being specifically enumerated, such as 'alanine' or 'Ala' or ' ⁇ ', the term refers to both L-alanine and D-alanine unless explicitly stated otherwise.
  • Other unconventional amino acids may also be suitable components for peptides of the present disclosure, as long as the desired functional property is retained by the peptide
  • Chemical derivatives of one or more amino acids may be achieved by reaction with a functional side group.
  • Such derivatives include, for example, those molecules in which free amino groups have been derivatized to form amine hydrochlorides, p-toluene sulphonyl groups, carboxybenzoxy groups, f-butyloxycarbonyl groups, chloroacetyl groups or formyl groups.
  • Free carboxyl groups may be derivatized to form salts, methyl and ethyl esters or other types of esters and hydrazides.
  • Free hydroxyl groups may be derivatized to form O-acyl or O-alkyl derivatives.
  • Also included as chemical derivatives are those peptides which contain naturally occurring amino acid derivatives of the twenty standard amino acids.
  • 4-hydroxyproline may be substituted for proline; 5-hydroxylysine may be substituted for lysine; 3-methylhistidine may be substituted for histidine; homoserine may be substituted for serine and ornithine for lysine.
  • Derivatives also include peptides containing one or more additions or deletions as long as the requisite activity is maintained. Other included modifications are amidation, amino terminal acylation (e.g. acetylation or thioglycolic acid amidation), terminal carboxylamidation (e.g. with ammonia or methylamine), and the like terminal modifications.
  • Some of the peptides of the disclosure shares amino acid sequence similarity with a sub-region of naturally occurring osteopontin proteins. In some embodiments, said peptide may be regarded as an active fragment of a naturally-occurring osteopontin protein or a variant of such as a fragment.
  • peptides of the disclosure shares amino acid sequence similarity with a sub-region of naturally occurring tenascin proteins.
  • said peptide may be regarded as an active fragment of a naturally-occurring tenascin protein or a variant of such as a fragment.
  • fragment at least 5 contiguous amino acids of the amino acid sequence are included, for example at least 6, 7, 8, 9, 10, 1 1 , 12, 13, 14 or 15 contiguous amino acids of the amino acid sequence.
  • the fragment may be 15 or fewer amino acids in length, for example 14, 13, 12, 1 1 , 10, 9, 8, 7, 6 or 5 amino acids in length
  • said peptide is of no more than no more than 85, such as no more than 80, such as no more than 75, such as no more than 70, such as no more than 65, such as no more than 60, such as nor more than 55, such as no more than 50, such as no more than 55, such as no more than 40 amino acids, such as no more than 35, such as no more than 30, such as no more than 28, such as no more than 26, such as no more than 24, such as no more than 22, such as no more than 20, such as no more than 19, such as no more than 18, such as no more than 17, such as no more than 16, such as no more than 15, such as no more than 14, such as no more than 13, such as no more than 12, such as no more than 1 1 , such as no more than 10 amino acids in length.
  • no more than 80 such as no more than 75, such as no more than 70, such as no more than 65, such as no more than 60, such as nor more than 55, such as no more than 50, such as no more than 55, such as no more than 40 amino acids,
  • said peptide is between 5 and 30 amino acids in length, such as between 5 and 20, such as between 8 and 20, such as between 8 and 16, such as between 10 and 15 amino acids in length.
  • said fragment comprises 15 or fewer amino acids in length, such as fewer than 14 amino acids, such as fewer than 13 amino acids, such as fewer than 12 amino acids, such as fewer than 1 1 amino acids, such as fewer than 10 amino acids, such as fewer than 9 amino acids, such as fewer than 8 amino acids, such as fewer than 7 amino acids, such as fewer than 6 amino acids, such as fewer than 5 amino acids in length.
  • variable refers to a peptide that does not share 100% amino acid sequence identity with the parent peptide, i.e. one or more amino acids must be mutated.
  • “Mutated” refers to altering an amino acid at a specified position in the parent peptide.
  • an amino acid at a specified position may be deleted, altered, substituted or may be the site of an insertion/addition of one or more amino acids. It will be appreciated by persons skilled in the art that the substitutions may be conservative or non-conservative.
  • said peptide variant comprises or consists of a sequence wherein no more than five amino acids are altered for another proteinogenic or non- proteinogenic amino acid, such as no more than 4 amino acids, such as no more than 3 amino acids, such as no more than 2 amino acids, such as no more than 1 amino acid is altered.
  • one or more amino acids are conservatively substituted.
  • Constantly substituted refers to a substitution of one amino acid with another with similar properties (size, hydrophobicity, etc), such that the function of the peptide is not significantly altered.
  • conservative substitutions is intended combinations such as Gly, Ala; Val, lie, Leu; Asp, Glu; Asn, Gin; Ser, Thr; Lys, Arg; and Phe, Tyr.
  • said peptide comprises or consists of one or more additional amino acids, inserted at the N- and/or C-terminus and/or internally within the sequence.
  • at least 2 additional amino acids such as at least 3, such as at least 4, such as at least 5, such as at least 6, such as at least 7, such as at least 8, such as at least 9, such as at least 10, such as at least 15 or such as at least 20 additional amino acids are inserted.
  • the additional amino acids may be the amino acids from the corresponding positions of the wildtype human osteopontin (SEQ ID NO: 66) or from the corresponding positions of the wildtype murine osteopontin (SEQ ID NO: 134).
  • the term "corresponding positions" of the wildtype osteopontin we mean that the additional amino acids are the same as those present in the equivalent position in the above wildtype osteopontin (if one imagines that the amino acid sequence of SEQ ID NO:1 replaces the sequence underlined in italics in SEQ ID NO:66
  • the peptide is selected from the group consisting of SEQ ID NO: 1 , 136, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, 50, 51 , 52, 53, 54, 55, 56, 57, 58, 59, 60, 61 , 62, 63, 64, 65, 67, 69, 70, 71 , 72, 73, 74, 75, 76, 77, 78, 79, 80, 81
  • GDISVVYGLRS SEQ ID NO 20 10-amino acid peptides:
  • ISVVYGLR SEQ ID NO: 43 ix. 7-amino acid peptides:
  • VDTYDGRGDSVVYGLR SEQ ID NO: 67 xiii. 15-amino acid peptides:
  • VDVPNGDISLAYGLR SEQ ID NO: 69
  • DVPNGDISLAYGLRS SEQ ID NO: 70 xiv. 14-amino acid peptides:
  • VDVPNGDISLAYGL SEQ ID NO: 71 DVPNGDISLAYGLR SEQ ID NO: 72
  • VPNGDISLAYGL SEQ ID NO: 80 PNGDISLAYGLR SEQ ID NO: 81
  • NGDISLAYGLR SEQ I D NO : 87 GDISLAYGLRS SEQ ID NO: 88 xviii.
  • 10-amino acid peptides VDVPNGDISL SEQ ID NO: 89 DVPNGDISLA SEQ ID NO: 90 VPNGDISLAY SEQ ID NO: 91 PNGDISLAYG SEQ ID NO: 92 NGDISLAYGL SEQ ID NO: 93 GDISLAYGLR SEQ ID NO: 94 DISLAYGLRS SEQ ID NO: 95 xix.
  • VDTYDGGISVVYGLR SEQ ID NO: 138 VDTYDGDGSVVYGLR SEQ ID NO: 139
  • KPLAEDISIELSYGIK SEQ ID NO: 144 KPLAEISDIELSYGIK SEQ ID NO: 145 KPLAEIGDIELSYGIK SEQ ID NO: 146
  • KPLAEIDSIELTYGIK SEQ ID NO: 149 KPLAEIDGIELSYGIK SEQ ID NO: 150
  • CFKPLAEIDSIEC SEQ ID NO: 156 xxxiv. 15-amino acid peptides:
  • VDVPEGDISLAYGLR SEQ ID NO: 157 LDGLVRAYDNISPVG SEQ ID NO: 158
  • said peptide is derived from osteopontin, such as a mammalian osteopontin variant and/or fragment.
  • said peptide is non-naturally occurring, such as a peptide comprising non-proteinogenic amino acid residues.
  • said peptide is further conjugated to a moiety, which may be selected from the group consisting of PEG, monosaccharides, fluorophores, chromophores, radioactive compounds, and cell-penetrating peptides.
  • the fluorophore is selected from the group consisting of Lucifer yellow, biotin, 5,6-carboxyltetramethylrhodamine ( TAMRA), indodicarbocyanine (C5) Alexa Fluor® 488, Alexa Fluor® 532, Alexa Fluor® 647, ATTO 488, ATTO 532, 6- carboxyfluorescein (6-FAM), Alexa Fluor® 350, DY-415, ATTO 425, ATTO 465, Bodipy® FL, fluorescein isothiocyanate, Oregon Green® 488, Oregon Green® 514, Rhodamine GreenTM, 5'-Tetrachloro-Fluorescein, ATTO 520, 6-carboxy-4',5'-dichloro- 2',7'-dimethoxyfluoresceine, Yakima YellowTM dyes, Bodipy® 530/550, hexachloro- fluorescein, Alexa Fluor® 555, DY-5
  • said peptide is further modified such as being glycosylated or by PEGylation, amidation, esterification, acylation, acetylation and/or alkylation.
  • said peptide comprises or consists of tandem repeats, which may comprise or consist of the amino acid sequence of any one or more of the sequences as described herein.
  • said peptide is cyclic.
  • the cyclic structure may be achieved by any suitable method of synthesis.
  • heterodetic linkages may include, but are not limited to formation via disulphide, cysteine, alkylene or sulphide bridges.
  • the peptide comprises or consists of a fusion.
  • the peptide may comprise a fusion of the amino acid sequence of SEQ ID NO: 1 or 136.
  • the term 'fusion' of a peptide relates to an amino acid sequence corresponding to, for example, SEQ ID NO: 1 or 136 (or a fragment or variant thereof) fused to any other peptide.
  • the said peptide may be fused to a polypeptide such as glutathione-S-transferase (GST) or protein A in order to facilitate purification of said peptide. Examples of such fusions are well known to those skilled in the art.
  • the said peptide may be fused to an oligo-histidine tag such as His6 or to an epitope recognised by an antibody such as the well-known Myc tag epitope. Fusions to any variant or derivative of said peptide are also included in the scope of the disclosure.
  • the fused portion may be a lipophilic molecule or peptide domain that is capable of promoting cellular uptake of the polypeptide, as known to those skilled in the art.
  • the present disclosure relates to a peptide comprising or consisting of an amino acid sequence selected from the group consisting of
  • KPLAEIDSIELSYGIK (SEQ ID NO: 136), GDPNDGRGDSVVYGLR (SEQ ID NO: 137), VDTYDGGISVVYGLR (SEQ ID NO: 138), and VDTYDGDGSVVYGLR (SEQ ID NO: 139), VDVPEGDISLAYGLR (SEQ ID NO: 157), LDGLVRAYDNISPVG (SEQ ID NO: 158), GDPNGDISVVYGLR (SEQ ID NO: 159), VDVPNGDISLAYRLR (SEQ ID NO: 160) VDVPEGDISLAYRLR (SEQ ID NO: 161 ), or a variant or fragment thereof.
  • the present disclosure relates to a peptide comprising or consisting of an amino acid sequence selected from the group consisting of
  • KCLAECDSIELSYGIK SEQ ID NO: 141
  • CLAEIDSC SEQ ID NO: 142
  • CFKPLAEIDSIECSYGIK (SEQ ID NO: 143), KPLAEDISIELSYGIK (SEQ ID NO: 145), KPLAEIGDIELSYGIK (SEQ ID NO: 146), KPLAEGDIELSYGIK (SEQ ID NO: 147), KPLAEIELSYGIK (SEQ ID NO: 148), KPLAEIDSIELTYGIK (SEQ ID NO: 149), KPLAEIDGIELSYGIK (SEQ ID NO: 150), KPLAEIDGIELTYGIK (SEQ ID NO: 151 ), KPLAEIGSIELSYGIK (SEQ ID NO: 152), KGLAEIDSIELSYGIK (SEQ ID NO: 153), KP LAG I DS IG LS YG I K (SEQ ID NO: 154), KCLAEIDSCELSYGIK (SEQ ID NO: 155) and CFKPLAEIDSIEC (SEQ ID NO: 156), or a variant or
  • KPLAEIDSIELSYGIK (SEQ ID NO: 136), or a variant or fragment thereof.
  • the present disclosure relates to the agent comprising a peptide, wherein the peptide comprises or consists of the amino acid sequence
  • the present disclosure relates to the agent comprising a peptide, wherein the peptide comprises or consists of the amino acid sequence
  • KGLAEIDSIELSYGIK (SEQ ID NO: 153), or a variant or fragment thereof.
  • the present disclosure relates to the agent comprising a peptide, wherein the peptide comprises or consists of the amino acid sequence
  • the present disclosure relates to the agent comprising a peptide, wherein the peptide comprises or consists of the amino acid sequence
  • KPLAEIDGIELTYGIK (SEQ ID NO: 151 ), or a variant or fragment thereof.
  • the present disclosure relates to the agent comprising a peptide, wherein the peptide comprises or consists of the amino acid sequence
  • KPLAEIGSIELSYGIK (SEQ ID NO: 152), or a variant or fragment thereof.
  • the present disclosure relates to the agent comprising a peptide, wherein the peptide comprises or consists of the amino acid sequence
  • KPLAEIELSYGIK (SEQ ID NO: 148), or a variant or fragment thereof.
  • the present disclosure relates to an agent comprising:
  • VDTYDGGISVVYGLR (SEQ ID NO: 138), and VDTYDGDGSVVYGLR
  • VDVPEGDISLAYGLR (SEQ ID NO: 157), LDGLVRAYDNISPVG (SEQ ID NO: 158), GDPNGDISVVYGLR (SEQ ID NO: 159), VDVPNGDISLAYRLR (SEQ ID NO: 160) VDVPEGDISLAYRLR (SEQ ID NO: 161 ), V(beta- D)TYDG D I S VVYG LR (SEQ ID NO:167), VDTY(beta- D)G D IS VVYG LR (SEQ ID NO: 168), VDTYDG(beta-
  • D)ISVVYGLR (SEQ ID NO:169); b) a polynucleotide encoding upon expression, the peptide of a);
  • said variant comprises or consists of a sequence wherein any one amino acid has been altered for another proteinogenic or non-proteinogenic amino acid, with the proviso that no more than five amino acids are so altered, such as no more than 4 amino acids, such as no more than 3 amino acids, such as no more than 2 amino acids, such as no more than 1 amino acid is altered. In some embodiments, one or more amino acids are conservatively substituted.
  • said peptide comprises or consists of one or more additional amino acids, inserted at the N- and/or C-terminus and/or internally within the sequence.
  • at least 2 additional amino acids such as at least 3, such as at least 4, such as at least 5, such as at least 6, such as at least 7, such as at least 8, such as at least 9, such as at least 10, such as at least 15 or such as at least 20 additional amino acids are inserted.
  • said peptide is no more than 85, such as no more than 80, such as no more than 75, such as no more than 70, such as no more than 65, such as no more than 60, such as nor more than 55, such as no more than 50, such as no more than 55, such as no more than 40 amino acids, such as no more than 35, such as no more than 30, such as no more than 28, such as no more than 26, such as no more than 24, such as no more than 22, such as no more than 20, such as no more than 19, such as no more than 18, such as no more than 17, such as no more than 16, such as no more than 15, such as no more than 14, such as no more than 13, such as no more than 12, such as no more than 1 1 , such as no more than 10 amino acids in length.
  • no more than 80 such as no more than 75, such as no more than 70, such as no more than 65, such as no more than 60, such as nor more than 55, such as no more than 50, such as no more than 55, such as no more than 40 amino acids, such as no more
  • said peptide is further conjugated to a moiety, which may be selected from the group consisting of PEG, monosaccharides, fluorophores, chromophores, radioactive compounds, and cell-penetrating peptides.
  • said peptide is further modified such as being glycosylated or by PEGylation, amidation, esterification, acylation, acetylation and/or alkylation.
  • said peptide comprises or consists of tandem repeats, which may comprise or consist of the amino acid sequence of any one or more of the sequences as described herein above.
  • said peptide is cyclic.
  • the cyclic structure may be achieved by any suitable method of synthesis.
  • heterodetic linkages may include, but are not limited to formation via, cysteine, disulphide, alkylene or sulphide bridges. Indications
  • the agents of the present disclosure are suitable for use in the treatment of endocrine, nutritional and metabolic diseases and disorders.
  • the mammal in need of treatment of an endocrine disease, a nutritional disease and/or a metabolic disease is a human.
  • the endocrine disease, nutritional disease and/or metabolic disease is selected from the group consisting of diabetes mellitus, type 1 diabetes mellitus, type 2 diabetes mellitus, malnutrition-related diabetes mellitus, disorders of glucose regulation and pancreatic internal secretion, insulin resistance syndrome, impaired glucose tolerance, hyperglycemia, hyperinsulinemia, and any combinations thereof.
  • the endocrine disease, nutritional disease and/or metabolic disease is selected from the group consisting of diabetes mellitus, disorders of the thyroid gland, disorders of glucose regulation and pancreatic internal secretion, disorders of endocrine glands, malnutrition, nutritional deficiencies, obesity,
  • diabetes mellitus is selected from the group consisting of type 1 diabetes mellitus, type 2 diabetes mellitus, malnutrition-related diabetes mellitus, specified diabetes mellitus, and unspecified diabetes mellitus.
  • disorders of glucose regulation and pancreatic internal secretion are selected from the group consisting of nondiabetic hypoglycaemic coma and disorders of pancreatic internal secretion.
  • disorders of obesity and hyperalimentation are selected from the group consisting of localized adiposity, hyperalimentation, and sequelae of
  • disorders of nutritional deficiencies are selected from the group consisting of disorders of aromatic amino-acid metabolism, disorders of branched- chain amino-acid metabolism and fatty-acid metabolism, disorders of amino-acid metabolism, lactose intolerance, disorders of carbohydrate metabolism, disorders of sphingolipid metabolism, disorders of lipid storage disorders, disorders of glycosaminoglycan metabolism, disorders of glycoprotein metabolism, disorders of lipoprotein metabolism, lipidaemias, disorders of purine and pyrimidine metabolism, disorders of porphyrin and bilirubin metabolism, disorders of mineral metabolism , cystic fibrosis, amyloidosis, volume depletion , disorders of fluid, electrolyte and acid- base balance, and postprocedural endocrine and metabolic disorders.
  • the present disclosure relates to a composition comprising the agent described herein.
  • the present disclosure relates to an agent selected from the group consisting of:
  • X 2 is C, P or G
  • X 5 is E or G
  • X 6 is C, D or I
  • X 7 is D, I, S or G
  • X 8 is S, D or G
  • X 12 is S or T
  • VDZ 3 Z 4 Z 5 GZ 7 Z 8 SZ 1 oZ 11 YGLR (SEQ ID NO: 68) wherein: Z 3 is T or V;
  • Z 4 is Y or P
  • Z 5 is D or N
  • Z 7 is D or G
  • Z 8 is I or G
  • a peptide comprising or consists of an amino acid sequence selected from the group consisting of KCLAECDSIELSYGIK (SEQ ID NO: 141 ), CLAEIDSC (SEQ ID NO: 142), CFKPLAEIDSIECSYGIK (SEQ ID NO: 143), KPLAEIELSYGIK (SEQ ID NO: 148), KCLAEIDSCELSYGIK (SEQ ID NO: 155) and CFKPLAEIDSIEC (SEQ ID NO: 156); b) a polynucleotide encoding upon expression, the peptide of a);
  • the present disclosure relates to a composition for use in treatment of an endocrine disease, a nutritional disease and/or a metabolic disease in a mammal.
  • a composition for use in treatment of an endocrine disease, a nutritional disease and/or a metabolic disease comprising an agent described herein.
  • said composition is a pharmaceutical composition.
  • the agent further comprises a second active ingredient.
  • Said second active ingredient may be selected from the group consisting of insulin, glucagon-like peptide-1 (GLP-1 ), biguanides, forskolin compounds, sulfonylurea, a dipeptidyl peptidase-4 (DPP4) inhibitor, an alpha-glucosidase inhibitor, a
  • GLP-1 glucagon-like peptide-1
  • DPP4 dipeptidyl peptidase-4
  • thiazolidinedione a meglitidine and a sodium-glucose cotransporter-2 (SGLT2) inhibitor.
  • the present disclosure concerns a method of treating an endocrine disease, a nutritional disease and/or a metabolic disease, the method comprising administering an agent described herein to a subject in need thereof.
  • the present disclosure concerns the use of an agent for the manufacture of a medicament for use in treatment of an endocrine disease, a nutritional disease and/or a metabolic disease in a mammal.
  • the present disclosure concerns a polynucleotide encoding upon expression the peptide as described herein. In one aspect, the present disclosure concerns a vector comprising said polynucleotide encoding upon expression the peptide as described herein. In one aspect, the present disclosure concerns a cell comprising said polynucleotide or said vector encoding upon expression the peptide as described herein
  • the present disclosure concerns a method for increasing insulin secretion, the method comprising administering a therapeutically effective amount of a peptide described herein, to an individual in need thereof.
  • said method is an in vitro method.
  • the present disclosure concerns a method for decreasing blood glucose levels, the method comprising administering a therapeutically effective amount of a peptide described herein, to an individual in need thereof.
  • said method is an in vitro method.
  • insulin secretion is increased.
  • cellular uptake of glucose is increased.
  • insulin production is increased.
  • glucagon production is decreased.
  • the present disclosure concerns a method, e.g. an in vitro method, for improving ⁇ - cell morphology, the method comprising administering a therapeutically effective amount of a peptide described herein, to an individual in need thereof.
  • the present disclosure concerns a method for improving ⁇ -cell viability, the method comprising administering a therapeutically effective amount of a peptide described herein, to an individual in need thereof.
  • the present disclosure concerns a method for delaying onset of diabetes and diabetes associated disorders and disease, the method comprising administering a therapeutically effective amount of a peptide described herein, to an individual in need thereof.
  • the agent may further comprise a detectable moiety.
  • a detectable moiety may comprise or consist of a radioisotope, such as a radioisotope selected from the group consisting of 99m Tc, In, 67 Ga, 68 Ga, 72 As, 89 Zr, 23 l and 20 TI.
  • the binding moieties may thus be coupled to nanoparticles that have the capability of multi-imaging (for example, SPECT, PET, MRI, Optical, or Ultrasound).
  • the detectable moiety may comprise or consist of a paramagnetic isotope, such as a paramagnetic isotope is selected from the group consisting of 57 Gd, 55 Mn, 62 Dy, 52 Cr and 56 Fe.
  • the agent comprises a detectable moiety
  • the detectable moiety may be detectable by an imaging technique such as SPECT, PET, MRI, optical or ultrasound imaging.
  • the present disclosure concerns the use of agent described herein for the preparation of a diagnostic composition for the diagnosis of a disease, disorder or damage of the pancreas in an individual.
  • An agent comprising:
  • X 2 is C, P or G
  • X 5 is E or G
  • X 6 is C, D or I
  • X 7 is D, I, S or G
  • X 8 is S, D or G
  • the peptide comprises no more than 25 amino acid residues
  • the peptide comprises no more than 85 amino acid residues; or a biologically active fragment and/or variant of SEQ ID NO: 140; b) a polynucleotide encoding upon expression, the peptide of a);
  • An agent comprising a peptide, wherein the peptide comprises an amino acid sequence of the general formula:
  • VDVPZ 5 GDISLAYZ 13 LR (SEQ ID NO: 164)
  • Z 5 is E or N
  • Z 13 is R or G.
  • An agent comprising a peptide, wherein the peptide comprises an amino acid sequence of the general formula:
  • VDTYDGZ 7 Z 8 S VVYG LR (SEQ I D NO : 165)
  • Z 7 is D or G
  • Z 8 is I or G.
  • An agent comprising a peptide, wherein the peptide comprises an amino acid sequence of the general formula:
  • Z 5 is D or G
  • Z 6 is D or G
  • Z 7 is I or R
  • Z 8 is G or absent
  • Z 9 is D or absent.
  • agent comprising:
  • VDVPEGDISLAYGLR SEQ ID NO: 157
  • LDGLVRAYDNISPVG SEQ ID NO: 158
  • GDPNGDISVVYGLR SEQ ID NO: 159
  • VDVPNGDISLAYRLR SEQ ID NO: 160
  • VDVPEGDISLAYRLR SEQ ID NO: 161
  • X 2 is C, P or G
  • X 5 is E or G; X 6 is C, I or absent;
  • X 7 is D, G or absent
  • X 8 is S, G or absent
  • X 2 is C, P or G
  • X 5 is E or G
  • An agent comprising:
  • VDVPEGDISLAYGLR (SEQ ID NO: 157), LDGLVRAYDNISPVG (SEQ ID NO: 158), GDPNGDISVVYGLR (SEQ ID NO: 159), VDVPNGDISLAYRLR (SEQ ID NO: 160) VDVPEGDISLAYRLR (SEQ ID NO: 161 ), V(beta-D)TYDGDISVVYGLR (SEQ ID NO: 157), LDGLVRAYDNISPVG (SEQ ID NO: 158), GDPNGDISVVYGLR (SEQ ID NO: 159), VDVPNGDISLAYRLR (SEQ ID NO: 160) VDVPEGDISLAYRLR (SEQ ID NO: 161 ), V(beta-D)TYDGDISVVYGLR (SEQ ID NO: 157), LDGLVRAYDNISPVG (SEQ ID NO: 158), GDPNGDISVVYGLR (SEQ ID NO: 159), VDVPNGDISLAYRLR (SEQ ID NO:
  • VDTY(beta-D)GDISVVYGLR SEQ ID NO: 168
  • VDTYDG(beta- D)ISVVYGLR SEQ ID NO:169
  • a cell comprising the polynucleotide of b), or the vector of c).
  • agent according to any one of the preceding items wherein the agent comprises non-naturally occurring, e.g. non-proteinogenic, amino acid residues.
  • agent according to any one of the preceding items wherein the agent is conjugated to a moiety.
  • moiety is selected from the group consisting of polyethylene glycol (PEG), monosaccharides, fluorophores, chromophores, radioactive compounds, and cell-penetrating peptides.
  • agent according to any one of the preceding items, wherein the agent is further modified such as being glycosylated or by PEGylation, amidation, esterification, acylation, acetylation and/or alkylation.
  • repeats comprise or consist of the amino acid sequence of any one or more of the sequences as described in the preceding items. 15. The agent according to any of the preceding items, wherein the agent is fused to another polypeptide.
  • polypeptide is selected from the group consisting of glutathione-S-transferase (GST) and protein A.
  • agent according to any of the preceding items wherein the agent is fused to a tag.
  • the agent according to any one of the preceding items wherein the said tag is an oligo-histidine tag.
  • the agent according to any of the preceding items, wherein the peptide or peptide analog comprises or consists of an amino acid sequence selected from the group consisting of KCLAECDSIELSYGIK (SEQ ID NO: 141 ), CLAEIDSC (SEQ ID NO: 142), CFKPLAEIDSIECSYGIK (SEQ ID NO: 143), KPLAEDISIELSYGIK (SEQ ID NO: 145), KPLAEIGDIELSYGIK (SEQ ID NO: 146), KPLAEGDIELSYGIK (SEQ ID NO: 147), KPLAEIELSYGIK (SEQ ID NO: 148), KPLAEIDSIELTYGIK (SEQ ID NO: 149), KPLAEIDGIELSYGIK (SEQ ID NO: 150), KPLAEIDGIELTYGIK (SEQ ID NO: 151 ), KPLAEIGSIELSYGIK (SEQ ID NO: 152), KGLAEIDSIELSYGIK (SEQ ID NO
  • peptide or peptide analog comprises or consists of the amino acid sequence KPLAGIDSIGLSYGIK (SEQ ID NO: 154), or a variant or fragment thereof.
  • peptide or peptide analog comprises or consists of the amino acid sequence KGLAEIDSIELSYGIK (SEQ ID NO: 153), or a variant or fragment thereof.
  • the agent according to any of the preceding items, wherein the peptide or peptide analog comprises or consists of the amino acid sequence KCLAECDSIELSYGIK (SEQ ID NO: 141 ), or a variant or fragment thereof.
  • the peptide or peptide analog comprises or consists of the amino acid sequence KPLAEIDGIELTYGIK (SEQ ID NO: 151 ), or a variant or fragment thereof.
  • the agent according to any of the preceding items, wherein the peptide or peptide analog comprises or consists of the amino acid sequence KPLAEIELSYGIK (SEQ ID NO: 148), or a variant or fragment thereof.
  • the variant comprises or consists of a sequence wherein any one amino acid has been altered for another proteinogenic or non-proteinogenic amino acid, with the proviso that no more than five amino acids are so altered.
  • the variant comprises or consists of a sequence wherein no more than five amino acids are altered for another proteinogenic or non-proteinogenic amino acid, such as no more than 4 amino acids, such as no more than 3 amino acids, such as no more than 2 amino acids, such as no more than 1 amino acid is altered.
  • the agent according to any one of the preceding items, wherein the peptide or peptide analog comprises or consists of one or more additional amino acids, inserted at the N- and/or C-terminus and/or internally within the sequence.
  • the agent comprises no more than 85, such as no more than 80, such as no more than 75, such as no more than 70, such as no more than 65, such as no more than 60, such as nor more than 55, such as no more than 50, such as no more than 55, such as no more than 40 amino acids, such as no more than 35, such as no more than 30, such as no more than 28, such as no more than 26, such as no more than 24, such as no more than 22, such as no more than 20, such as no more than 19, such as no more than 18, such as no more than 17, such as no more than 16, such as no more than 15, such as no more than 14, such as no more than 13, such as no more than 12, such as no more than 1 1 , such as no more than 10 amino acids.
  • the agent comprises at least 2 additional amino acids, such as at least 3, such as at least 4, such as at least 5, such as at least 6, such as at least 7, such as at least 8, such as at least 9, such as at least 10, such as at least 15 or such as at least 20 amino acids conjugated to the N- or C-terminus of the peptide.
  • the detectable moiety comprises or consists of a radioisotope.
  • the radioisotope is selected from the group consisting of 99m Tc, ⁇ , 67 Ga, 68 Ga, 72 As, 89 Zr, 23 l and 2 01 TI.
  • the detectable moiety is detectable by an imaging technique such as SPECT, PET, MRI, optical or ultrasound imaging.
  • composition comprising the agent according to any of the preceding items.
  • composition is a pharmaceutical composition.
  • X 2 is C, P or G
  • X 5 is E or G
  • X 6 is C, D or I
  • X 7 is D, I, S or G
  • X 8 is S, D or G
  • the peptide comprises no more than 25 amino acid residues; or a biologically active fragment and/or variant of SEQ ID NO: 140;
  • Z 3 is T or V
  • Z 4 is Y or P
  • Z 5 is D or N
  • Z 7 is D or G
  • Z 8 is I or G; b) a polynucleotide encoding upon expression, the peptide of a);
  • peptide for use in the treatment of an endocrine disease, a nutritional disease and/or a metabolic disease in a mammal.
  • agent or the composition for use according to item 44, wherein the peptide comprises or consists of an amino acid sequence selected from the group consisting of KCLAECDSIELSYGIK (SEQ ID NO: 141 ), CLAEIDSC (SEQ ID NO:
  • CFKPLAEIDSIECSYGIK SEQ ID NO: 143
  • KPLAEIELSYGIK SEQ ID NO: 148
  • KCLAEIDSCELSYGIK SEQ ID NO: 155
  • CFKPLAEIDSIEC SEQ ID NO: 156
  • the agent or the composition for use according to any one of the preceding items wherein the peptide is selected from the group consisting of SEQ ID NO: 1 , 136, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, 50, 51 , 52, 53, 54, 55, 56, 57, 58, 59, 60, 61 , 62, 63, 64, 65, 67, 69, 70, 71 , 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91 , 92, 93, 94, 95, 96, 97, 98, 99, 100, 101 , 102,
  • agent or the composition for use according to any one of the preceding items wherein said agent comprises a second or further active ingredient.
  • GLP-1 glucagon- like peptide-1
  • DPP4 dipeptidyl peptidase-4
  • alpha-glucosidase inhibitor a thiazolidinedione
  • meglitidine a meglitidine
  • SGLT2 sodium-glucose cotransporter-2
  • the agent or the composition according to any of the preceding items for use in the treatment of an endocrine disease, a nutritional disease and/or a metabolic disease in a mammal.
  • the agent or the composition for use according to item 50 wherein the mammal is a human.
  • the agent or the composition for use according to any one of the preceding items, wherein the endocrine disease, nutritional disease and/or metabolic disease are selected from the group consisting of diabetes mellitus, type 1 diabetes mellitus, type 2 diabetes mellitus, malnutrition-related diabetes mellitus, disorders of glucose regulation and pancreatic internal secretion, insulin resistance syndrome, impaired glucose tolerance, hyperglycemia, hyperinsulinemia, and any combinations thereof.
  • the endocrine disease, nutritional disease and/or metabolic disease are selected from the group consisting of diabetes mellitus, disorders of the thyroid gland, disorders of glucose regulation and pancreatic internal secretion, disorders of endocrine glands, malnutrition, nutritional deficiencies, obesity,
  • the agent or the composition for use according to any one of the preceding items wherein the diabetes mellitus is selected from the group consisting of type 1 diabetes mellitus, type 2 diabetes mellitus, malnutrition-related diabetes mellitus, specified diabetes mellitus, and unspecified diabetes mellitus.
  • the agent or the composition for use according to any one of the preceding items wherein the disorder of glucose regulation and pancreatic internal secretion is selected from the group consisting of nondiabetic hypoglycaemic coma and disorders of pancreatic internal secretion.
  • the agent or the composition for use according to any one of the preceding items, wherein the disorder of obesity and hyperalimentation is selected from the group consisting of localized adiposity, hyperalimentation, and sequelae of
  • the disorder of nutritional deficiencies is selected from the group consisting of disorders of aromatic amino-acid metabolism, disorders of branched-chain amino-acid metabolism and fatty-acid metabolism, disorders of amino-acid metabolism, lactose intolerance, disorders of carbohydrate metabolism, disorders of sphingolipid metabolism, disorders of lipid storage disorders, disorders of glycosaminoglycan metabolism, disorders of glycoprotein metabolism, disorders of lipoprotein metabolism, lipiemias, disorders of purine and pyrimidine metabolism, disorders of porphyrin and bilirubin metabolism, disorders of mineral metabolism , cystic fibrosis, amyloidosis, volume depletion, disorders of fluid, electrolyte and acid-base balance, and postprocedural endocrine and metabolic disorders.
  • a method of treating an endocrine disease, a nutritional disease and/or a metabolic disease comprising administering an agent according to any one of the preceding items to a subject in need thereof.
  • a method for delaying onset of diabetes and diabetes associated disorders and diseases the method comprising administering a therapeutically effective amount of the agent as defined in any one of the preceding items, to an individual in need thereof.
  • a method for decreasing blood glucose levels comprising
  • a method for improving beta cell viability the method comprising administering a therapeutically effective amount of an agent of any one of the preceding items, to an individual in need thereof.
  • a method for improving beta cell morphology the method comprising administering a therapeutically effective amount of an agent of any one of the preceding items, to an individual in need thereof.
  • a method for stabilising or improving viability and/or morphology of pancreatic islets comprising administering a therapeutically effective amount of an agent of any one of the preceding items, to an individual in need thereof.
  • exemplary peptides of the present disclosure stimulate ⁇ — cell proliferation, and have the ability to protect and rescue ⁇ — cells from apoptosis induced by glucotoxic conditions. It is also demonstrated that the exemplary peptides have the ability to stimulate insulin secretion from rat ⁇ -cells as well as isolated mouse pancreatic islets, where the peptides also are demonstrated to reduce glucagon levels. Furthermore, the examples demonstrate that the peptides reduce plasma glucose levels in vivo in a glucose tolerance test and that the peptides delay onset of type 1 diabetes in BB lyp/lyp rats
  • the novel peptides were designed following rational structure activity investigations.
  • FOL-005 SEQ ID NO: 1
  • the peptides were designed around the RGD site but mutated in order to generate different structures that potentially could interact with different integrins.
  • a sequence similar to FOL-005 was identified in the third fibronectin type III repeat domain (TNfn3) in tenascin-C and found to be reasonably similar to the mutated RGD site of FOL-005.
  • a peptide was designed from this sequence denoted FOL-014.
  • the X-ray crystal structure of the tenascin-3 TNfn3 domain (PDB code 1 TEN, Leahy et al.
  • FOL-014 SEQ ID NO: 1366
  • FOL-014 variants were designed to allow for structural modification and stabilization of the 3-dimensional molecular structure. Specifically, the peptides variants covered the beta-turn region with exposed side chains and some cyclized variants to maintain geometry.
  • Rat INS-1 cells were seeded in 96-well plates in RPMI medium with supplement and after 2 hours the medium was changed to RPMI without supplement. During the proliferation experiment the cells were incubated at different test conditions (FOL-005, FOL-014, coated or in solution, 48h incubation) and during the last 20 hours of culture period the cells were pulsed with 1 ⁇ Ci/well of [methyl-3H] thymidine. The cells were then harvested onto glass fiber filters using a FilterMate harvester. The filters were air dried, and the bound radioactivity was measured using a liquid scintillation counter.
  • FOL-005 INS-1 cells were treated with increasing amounts of soluble FOL-005 (0.06-6 ⁇ ) during 48 hours and proliferation was measured with radiolabeled thymidine incorporation into newly synthesized DNA.
  • FOL-005 stimulated INS-1 cell proliferation (Fig. 1 A).
  • Wells coated with either FOL-005 or FOL-014 and later blocked with bovine serum albumin (BSA) before addition of INS-1 cells also stimulated proliferation compared to control (Ctrl) coated wells (Fig. 1 B-C).
  • INS-1 cells Exposure of INS-1 cells to 20 mM of glucose at the same time as FOL-005 decreased cell apoptosis as detected both by Annexin V staining and by caspase-3 activity (Fig.2 A-B).
  • the rate of apoptosis in INS-1 cells was measured with either Caspase-3 Assay Kit or stained with Annexin V Apoptosis Detection Kit with 7-AAD.
  • Caspase-3 activity was measured with fluorescence at an excitation wavelength of 380 nm and an emission wavelength of 440 nm. Caspase-3 activity was then normalized to protein concentration in each well. Measurements of Annexin V stained cells were performed using a CyAn ADP flow cytometer and analyzed with Summit V4.3 software.
  • INS-1 ⁇ -cells were used in the following experiments. Cells were seeded overnight in cRPMI and then washed with PBS before pre-incubation for 60 min at 37° C in Krebs-Ringer bicarbonate buffer (KRB), pH 7.4, supplemented with 10 mM HEPES, 0.1 % bovine serum albumin. After pre-incubation, the buffer was changed and the INS-1 cells were incubated at different test conditions (0 mM, 5 mM or 20 mM glucose) and stimulated with peptide FOL-005 or FOL-015 (SEQ ID NO: 158) or left untreated during 60 min at 37° C. Immediately after incubation, an aliquot of the buffer was removed and frozen for subsequent assay of insulin with an insulin radioimmunoassay kit.
  • KRB Krebs-Ringer bicarbonate buffer
  • Mouse pancreatic islets were isolated from 8-week old C57BL/6J male mice (Taconic). Mice were sacrificed by an overdose of isoflurane and cervical dislocation. 3 ml of 0.9 U/ml collagenase P was injected into the pancreatic duct to inflate the pancreas. The pancreas was then removed and collagen digested for 19 min at 37 °C. The samples were vigorously shaken to disrupt the tissue. The digest was transferred into ice cold Hank's Balanced Salt Solution (HBSS) with Ca 2+ and Mg 2+ . The suspension was allowed to sit for 10 min to allow the islet to sink, and the islets were washed in fresh HBSS four times.
  • HBSS Hank's Balanced Salt Solution
  • INS-1 ⁇ -cells were used to investigate the stimulatory effect of FOL-014 on insulin secretion.
  • Cells were seeded overnight and then washed with PBS before preincubation for 60 min at 37° C in Krebs-Ringer bicarbonate buffer (KRB), pH 7.4, supplemented with 10 mM HEPES, 0.1 % bovine serum albumin.
  • KRB Krebs-Ringer bicarbonate buffer
  • the buffer was changed and the INS-1 cells were incubated in new KRB buffer supplemented with 10 mM HEPES, 0.1 % bovine serum albumin and stimulated with peptide FOL-014 or left untreated during 60 min at 37° C.
  • an aliquot of the buffer was removed and frozen for subsequent assay of insulin.
  • Example 7 FOL-014 induced insulin secretion from mouse pancreatic islets
  • Example 8-11 Stimulation of insulin secretion from INS-1 cell lines by FOL-014, FOL-005 and related peptides
  • Rat INS-1 ⁇ -cells (passages 60-70) were cultured at 37 °C and 5% C0 2 in cRPMI media (RPMI 1640 supplemented with 10% fetal bovine serum, 50 lU/mL penicillin, 50 mg/L streptomycin, 10 mM HEPES, 2 mM L-glutamine, 1 mM sodium pyruvate, and 50 ⁇ beta-mercaptoethanol) unless otherwise stated.
  • cRPMI media RPMI 1640 supplemented with 10% fetal bovine serum, 50 lU/mL penicillin, 50 mg/L streptomycin, 10 mM HEPES, 2 mM L-glutamine, 1 mM sodium pyruvate, and 50 ⁇ beta-mercaptoethanol
  • INS-1 cells were seeded in 96-well plates (2x 10 3 cells/well) in cRPMI medium and following overnight incubation, the cells were washed in PBS before pre-incubation for 120 min at 37° C in Krebs-Ringer bicarbonate buffer, pH 7.4, supplemented with 10 mM HEPES, 0.1 % bovine serum albumin and 2.8 mM glucose. Following pre-incubation, the buffer was exchanged with fresh Krebs-Ringer buffer as described above and supplemented with specific glucose concentrations and peptides for the individual experiments as described below. Immediately after 60 minutes incubation at 37 C, an aliquot of the buffer was removed and frozen for subsequent insulin ELIZA assay.
  • Example 8 FOL-014 induced insulin secretion is dose-dependent in a non-linear manner
  • Insulin release from INS-1 cells were measured following exposure to increasing concentrations of FOL-014 and compared with the stimulatory effect of GLP-1 and untreated control during high glucose concentration (16.7 mM). All concentrations of FOL-014 tested elicited significantly higher insulin release as compared with the untreated control. At 6 nM or higher, FOL-014 triggered insulin release within the same range as 100 mM GLP-1 . At concentrations ranging from 0.6-60 nM, insulin secretion increased in a linear fashion in relation to increasing FOL-014 concentrations. Exposure to FOL-014 concentrations ⁇ 600 nM did not increase the insulin secretion (Figure 5).
  • Example 9 The capacity of FOL-014 to induce insulin secretion is glucose dependent
  • Insulin release from INS-1 cells was measured following exposure to 60 nM FOL-014 at increasing concentrations of glucose.
  • elevated glucose concentrations increased the insulin secretion at 1 1 .1 mM glucose or higher.
  • insulin secretion increased significantly in a glucose dependent fashion already from 5.5 mM glucose.
  • Figure 6 The results demonstrated that the presence of FOL-014 significantly increased insulin secretion from INS-1 ⁇ -cells in vitro in a glucose concentration dependent fashion and that FOL-014 was effective also at marginally elevated glucose levels.
  • Example 10 FOL-014 or FOL-005 in combination with GLP-1 increased insulin secretion as compared with either peptide alone.
  • Insulin secretion from INS-1 cells was measured following exposure to FOL-005, FOL- 014, GLP-1 or combinations of those, expressed as percentage of untreated control.
  • the combined effect of GLP-1 and FOL-014 resulted in a significantly higher insulin release than GLP-1 or FOL-014 alone.
  • the additive effect of the combination of FOL- 005 and GLP-1 was less pronounced, but did however increase the insulin secretion as compared with GLP-1 alone.
  • the experiments were performed in the presence of 16.7 mM glucose (Figure 7). The results demonstrated that the combination of GLP-1 and FOL-014 could further potentiate the insulin secretion from INS-1 cells in vitro as compared with each peptide alone.
  • the combination of FOL-005 and GLP-1 tendentially increased insulin secretion.
  • Example 11 The ability of novel peptide analogues to induce insulin secretion in pancreatic ⁇ -cell-lines was investigated
  • Novel peptide analogues derived from either FOL-005 or FOL-014 were tested concerning their ability to induce insulin secretion in two separate INS-1 cell lines in the presence of 16.7 mM glucose.
  • FOL-005, FOL-014 and GLP-1 as well as a high glucose (16.7 mM) and a low glucose (2.8 mM) control (not shown) was included in each experiment and the peptide concentration was 100 nM.
  • All values were normalized to, and expressed as percentage of the average value of the high glucose control in the individual experiments.
  • the analogues were subsequently ranked according to performance ( Figure 1 1 A and 1 1 B). Peptide analogues eliciting an insulin response below the high glucose control average value were considered non-functional and were hence excluded (not shown).
  • Freshly isolated islets were seeded in groups of 5 in a 96-well plate and preincubated for 1 h at 37°C in a Krebs-Ringer bicarbonate buffer (pH 7.4). The islets were incubated for 1 h at 37 ⁇ in Krebs-Ringer buffered solution supplemented with 0.6 or 6 ⁇ FOL- 014 or 100 nM GLP-1 or left unsupplemented for control. Immediately after incubation, the medium was removed for assays of insulin and glucagon using Mercodia's ELISA kits.
  • mice Whole blood was collected for glucose and insulin measurements from 10-week-old wild type maleC57bl/6 mice. After a 4 hour fast, the mice were divided into three groups and given an intraperitoneal injection (ip) of either saline, 30 nmol/kg peptide ( Figure 9A) or 200 nmol/kg peptide ( Figure 9B). 15 min after the FOL-014 or saline (control) injections, the mice were administered 2 g of glucose/kg ip. Blood glucose concentrations were measured at 5, 15, 30, 45 and 60 minutes after the glucose injection. Statistical calculations were performed using student's t-test. FOL-014 dosed at 200 nmol/kg significantly lowered the plasma glucose levels as compared to the control when measured as area under the curve. In addition, the difference was significant at 15, 30 and 45 minutes. At the 30 nmol/kg dose, FOL-014 lowered the plasma glucose levels with a significant effect at 45 minutes after the glucose injection.
  • ip intraperitoneal injection
  • FOL-014 could lower plasma glucose levels in a glucose tolerance test performed on healthy wild type mice.
  • Example 14 FOL-014 delayed onset of Type 1 Diabetes in BB lyp/lyp rats
  • BB lyp/lyp rats were randomized for placebo (sodium chloride, 9 mg/ml) or FOL-014 treatment 3 times/week from day 40 until onset of type 1 diabetes, defined as plasma glucose levels > 1 1 .1 mM.
  • the dose of 100 nmol/kg FOL-014 peptide in saline or placebo (saline) was administered subcutaneously and the animals were terminated immediately upon exceeding critical plasma glucose levels.
  • the difference between FOL-014 treated animals and animals receiving placebo treatment was significant both when expressed as average age for onset of type 1 diabetes (Figure 10A) and when described as percentage of animals developing type 1 diabetes per day ( Figure 10B).
  • each peptide was 10 nmol per mouse.
  • the mice were imaged before injection, at 5min, 20min, 50min, 60min, 2hrs, 4hrs, 6hrs, 24hrs and 48 hrs post administration of labelled peptide.
  • Example 16 Tissue specific imaging for diagnostic use
  • Agents prepared as defined herein above are labelled by conjugation to suitable imaging probe or moiety, using methods known by those of skill in the art.
  • the conjugated peptide-probe agents are subsequently administered to a subject and biodistribution is subsequently monitored e.g. up to 48h after administration.
  • the conjugated agent is thus used as a diagnostic or prognostic tool for investigation of pancreatic status.
  • the conjugated agents are suitable for detecting, diagnosing, or monitoring disease, disease processes and progression, susceptibility, as well as to determine efficacy of a treatment.
  • the agents are particularly suited for monitoring the diabetic status of a subject.
  • the conjugated agents are also used for monitoring and/or predicting risk of developing a disease, specifically diabetes.
  • the test is used alone or in combination with other tests known by those of skill in the art, such as blood tests, genetic testing, urine test, and biopsies.
  • NKYPDAVATWLNPDPSQKQNLLAPQTLPSK osteopontin i.e.
  • VDZ 3 Z 4 Z 5 GZ 7 Z 8 SZ 1 oZ 1 1 YGLR Z 3 is T or V;
  • KX 2 LAX 5 X 6 X 7 X 8 lXi oLX 12 YG I K X 2 is C, P or G;
  • X 5 is E or G;
  • X 6 is C, D or I;
  • X 7 is D, I, S or G;
  • X 8 is S, D or G;

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/EP2018/061547 2017-05-04 2018-05-04 Peptides for treatment of diabetes Ceased WO2018202870A1 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
EA201992562A EA201992562A1 (ru) 2017-05-04 2018-05-04 Пептиды для лечения сахарного диабета
AU2018262805A AU2018262805B2 (en) 2017-05-04 2018-05-04 Peptides for treatment of diabetes
BR112019021886-6A BR112019021886A2 (pt) 2017-05-04 2018-05-04 Peptídeos para o tratamento de diabetes
JP2019555219A JP2020518556A (ja) 2017-05-04 2018-05-04 糖尿病の処置のためのペプチド
PL18721806T PL3618845T3 (pl) 2017-05-04 2018-05-04 Peptydy do leczenia cukrzycy
IL270199A IL270199B2 (en) 2017-05-04 2018-05-04 Peptides for the treatment of diabetes
KR1020197027946A KR102700014B1 (ko) 2017-05-04 2018-05-04 당뇨병 치료용 펩타이드
SG11201908513R SG11201908513RA (en) 2017-05-04 2018-05-04 Peptides for treatment of diabetes
EP18721806.0A EP3618845B1 (en) 2017-05-04 2018-05-04 Peptides for treatment of diabetes
CN201880026723.5A CN110545834B (zh) 2017-05-04 2018-05-04 用于治疗糖尿病的肽
DK18721806.0T DK3618845T3 (da) 2017-05-04 2018-05-04 Peptider til behandling af diabetes
ES18721806T ES2857749T3 (es) 2017-05-04 2018-05-04 Péptidos para el tratamiento de la diabetes
MX2019013096A MX2019013096A (es) 2017-05-04 2018-05-04 Peptidos para el tratamiento de diabetes.
CA3061935A CA3061935A1 (en) 2017-05-04 2018-05-04 Peptides for treatment of diabetes
ZA2019/05891A ZA201905891B (en) 2017-05-04 2019-09-06 Peptides for treatment of diabetes
US16/666,960 US10815283B2 (en) 2017-05-04 2019-10-29 Peptides for treatment of diabetes
US17/022,526 US20210009648A1 (en) 2017-05-04 2020-09-16 Peptides for treatment of diabetes
JP2023051477A JP2023082076A (ja) 2017-05-04 2023-03-28 糖尿病の処置のためのペプチド
JP2025037548A JP2025090703A (ja) 2017-05-04 2025-03-10 糖尿病の処置のためのペプチド

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17169500 2017-05-04
EP17169500.0 2017-05-04

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/666,960 Continuation US10815283B2 (en) 2017-05-04 2019-10-29 Peptides for treatment of diabetes

Publications (1)

Publication Number Publication Date
WO2018202870A1 true WO2018202870A1 (en) 2018-11-08

Family

ID=58671461

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/061547 Ceased WO2018202870A1 (en) 2017-05-04 2018-05-04 Peptides for treatment of diabetes

Country Status (17)

Country Link
US (2) US10815283B2 (enExample)
EP (1) EP3618845B1 (enExample)
JP (3) JP2020518556A (enExample)
KR (1) KR102700014B1 (enExample)
CN (1) CN110545834B (enExample)
AU (1) AU2018262805B2 (enExample)
BR (1) BR112019021886A2 (enExample)
CA (1) CA3061935A1 (enExample)
DK (1) DK3618845T3 (enExample)
EA (1) EA201992562A1 (enExample)
ES (1) ES2857749T3 (enExample)
IL (1) IL270199B2 (enExample)
MX (1) MX2019013096A (enExample)
PL (1) PL3618845T3 (enExample)
SG (1) SG11201908513RA (enExample)
WO (1) WO2018202870A1 (enExample)
ZA (1) ZA201905891B (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020094797A1 (en) * 2018-11-07 2020-05-14 Follicum Ab Peptide fragments for treatment of diabetes
WO2020216896A1 (en) * 2019-04-24 2020-10-29 Follicum Ab Topical formulation
WO2023218094A1 (en) * 2022-05-13 2023-11-16 Coegin Pharma Ab Agents inducing vascularisation
WO2023218095A1 (en) * 2022-05-13 2023-11-16 Coegin Pharma Ab Agents for stimulating tissue regeneration
EP4501943A4 (en) * 2022-03-24 2025-08-27 Caregen Co Ltd PEPTIDE HAVING ANTIDIABETIC ACTIVITY, PEPTIDE COMPLEX AND ITS USE

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009058379A2 (en) * 2007-10-31 2009-05-07 Medimmune, Llc Protein scaffolds
US7662633B2 (en) * 2000-03-23 2010-02-16 Glaxosmithkline Llc Method of screening for inhibitors of osteopontin
US20100150877A1 (en) * 2007-03-02 2010-06-17 National University Of Ireland, Galway Osteopontin for the Prediction and Treatment of Cardiovascular Diseases
WO2015159099A1 (en) * 2014-04-17 2015-10-22 Follicum Ab Compositions comprising osteopontin derivatives for the inhibition of hair growth
US20160317620A1 (en) * 2011-08-10 2016-11-03 Folicum Ab Novel Compositions and Uses Thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996008513A1 (en) * 1994-09-16 1996-03-21 The Scripps Research Institute Cytotactin derivatives that stimulate attachment and neurite outgrowth, and methods of making and using same
WO1999015904A1 (en) 1997-09-26 1999-04-01 University Of Washington Methods and compositions for diagnosing renal pathologies
US6551990B2 (en) 1998-12-07 2003-04-22 University Of Washington Methods of inhibiting ectopic calcification
IL153206A0 (en) 2000-06-13 2003-07-06 Childrens Medical Center Biosynthetic oncolytic molecules and uses therefor
PL211763B1 (pl) 2001-05-17 2012-06-29 Serono Lab Zastosowanie osteopontyny, cząsteczki kwasu nukleinowego, komórki zmodyfikowanej genetycznie oraz kompozycja farmaceutyczna
JP4351043B2 (ja) 2001-07-09 2009-10-28 エラン ファーマシューティカルズ，インコーポレイテッド アミロイド毒性の阻害方法
WO2003100007A2 (en) 2002-05-24 2003-12-04 Schering-Plough Ltd. Eta-1 gene and methods for use
US20070274993A1 (en) * 2003-05-23 2007-11-29 Immuno-Biological Laboratories Co., Ltd. Immunocompetent Cell Activation Inhibitor and Use Thereof
WO2008086449A2 (en) 2007-01-09 2008-07-17 Oregon Health & Science University Synthetic osteopontin peptides and methods of use
CA2684254A1 (en) 2007-04-17 2008-10-30 Pfizer Inc. Method for controlling glucose uptake and insulin sensitivity
CN101293916A (zh) 2007-04-24 2008-10-29 上海国健生物技术研究院 骨桥蛋白的功能表位、与其特异性结合的单克隆抗体及用途
CN101215324B (zh) * 2007-12-26 2010-11-24 吉林大学 艾塞那肽短肽模拟肽及其在制备糖尿病治疗药物中的应用
WO2011058182A1 (en) 2009-11-13 2011-05-19 National University Of Ireland, Galway Osteopontin-conditioned medium for the treatment of vascular diseases
CN104640989A (zh) 2012-07-20 2015-05-20 阿拉食品公司 用于抑制或防止肿瘤生长的骨桥蛋白肽片段
AU2017260003B2 (en) 2016-05-06 2019-12-05 Astrazeneca Ab GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662633B2 (en) * 2000-03-23 2010-02-16 Glaxosmithkline Llc Method of screening for inhibitors of osteopontin
US20100150877A1 (en) * 2007-03-02 2010-06-17 National University Of Ireland, Galway Osteopontin for the Prediction and Treatment of Cardiovascular Diseases
WO2009058379A2 (en) * 2007-10-31 2009-05-07 Medimmune, Llc Protein scaffolds
US20160317620A1 (en) * 2011-08-10 2016-11-03 Folicum Ab Novel Compositions and Uses Thereof
WO2015159099A1 (en) * 2014-04-17 2015-10-22 Follicum Ab Compositions comprising osteopontin derivatives for the inhibition of hair growth

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LEAHY ET AL., SCIENCE, vol. 258, no. 5084, 1992, pages 987 - 91
SAROSIEK KONRAD ET AL: "Osteopontin (OPN) Isoforms, Diabetes, Obesity, and Cancer; What Is One Got to Do with the Other? A New Role for OPN", JOURNAL OF GASTROINTESTINAL SURGERY, QUALITY MEDICAL PUBL., ST. LOUIS, MO, US, vol. 19, no. 4, 13 January 2015 (2015-01-13), pages 639 - 650, XP035471322, ISSN: 1091-255X, [retrieved on 20150113], DOI: 10.1007/S11605-014-2735-6 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020094797A1 (en) * 2018-11-07 2020-05-14 Follicum Ab Peptide fragments for treatment of diabetes
CN113164548A (zh) * 2018-11-07 2021-07-23 富力卡姆股份公司 用于治疗糖尿病的肽片段
JP2022516400A (ja) * 2018-11-07 2022-02-28 フォリクム エービー 糖尿病治療のためのペプチド断片
JP7553115B2 (ja) 2018-11-07 2024-09-18 フォリクム エービー 糖尿病治療のためのペプチド断片
WO2020216896A1 (en) * 2019-04-24 2020-10-29 Follicum Ab Topical formulation
CN114007589A (zh) * 2019-04-24 2022-02-01 富力卡姆股份公司 局部制剂
JP2022530036A (ja) * 2019-04-24 2022-06-27 フォリクム エービー 局所製剤
EP4501943A4 (en) * 2022-03-24 2025-08-27 Caregen Co Ltd PEPTIDE HAVING ANTIDIABETIC ACTIVITY, PEPTIDE COMPLEX AND ITS USE
WO2023218094A1 (en) * 2022-05-13 2023-11-16 Coegin Pharma Ab Agents inducing vascularisation
WO2023218095A1 (en) * 2022-05-13 2023-11-16 Coegin Pharma Ab Agents for stimulating tissue regeneration

Also Published As

Publication number Publication date
CA3061935A1 (en) 2018-11-08
AU2018262805B2 (en) 2022-02-17
US20210009648A1 (en) 2021-01-14
ZA201905891B (en) 2022-03-30
JP2023082076A (ja) 2023-06-13
MX2019013096A (es) 2019-12-16
EA201992562A1 (ru) 2020-07-01
SG11201908513RA (en) 2019-11-28
BR112019021886A2 (pt) 2020-06-02
KR102700014B1 (ko) 2024-08-29
JP2020518556A (ja) 2020-06-25
KR20200003369A (ko) 2020-01-09
US10815283B2 (en) 2020-10-27
IL270199B2 (en) 2024-07-01
IL270199B1 (en) 2024-03-01
AU2018262805A1 (en) 2019-11-21
CN110545834B (zh) 2024-02-20
EP3618845A1 (en) 2020-03-11
ES2857749T3 (es) 2021-09-29
EP3618845B1 (en) 2021-01-13
PL3618845T3 (pl) 2021-08-02
CN110545834A (zh) 2019-12-06
US20200095297A1 (en) 2020-03-26
DK3618845T3 (da) 2021-04-19
IL270199A (en) 2019-12-31
JP2025090703A (ja) 2025-06-17

Similar Documents

Publication Publication Date Title
US10815283B2 (en) Peptides for treatment of diabetes
US20240327459A1 (en) Peptide fragments for treatment of diabetes
ES2334864T3 (es) Peptido-2 analogo al glucagon y su uso terapeutico.
JP3262329B2 (ja) 糖尿病治療に有用なｇｌｐ―１アナログ
JPH04507240A (ja) インシュリン様成長因子及び類似体を用いる障害治療方法
RU2206336C2 (ru) Фрагмент с-пептида человеческого проинсулина
WO2011153491A2 (en) Agonists of growth hormone releasing hormone as effectors for survival and proliferation of pancreatic islets
US20100221240A1 (en) Chemically Modified Peptide Analogs
PT2212349E (pt) Análogos sintéticos de péptidos de regeneração neural
HK40017988B (en) Peptides for treatment of diabetes
HK40017988A (en) Peptides for treatment of diabetes
EP4648849A1 (en) Nmu receptor 2 agonists
WO2012038957A1 (en) Ktpaf50 (prt3) for treating diseases of the pancreas
Do SunGil et al. Silk fibroin hydrolysate exerts an anti-diabetic effect by increasing pancreatic β cell mass in C57BL/KsJ-db/db mice.
HK1125653A (en) Derivatives of glucagon-like peptide-2 and their therapeutic use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18721806

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 20197027946

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019555219

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3061935

Country of ref document: CA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019021886

Country of ref document: BR

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018262805

Country of ref document: AU

Date of ref document: 20180504

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018721806

Country of ref document: EP

Effective date: 20191204

ENP Entry into the national phase

Ref document number: 112019021886

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20191018